Foghorn Therapeutics/$FHTX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Foghorn Therapeutics
Foghorn Therapeutics Inc is a clinical stage, precision therapeutics biotechnology company focused on pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression through selectively targeting the chromatin regulatory system. Its proprietary platform is designed to provide an integrated, mechanistic understanding of interactions within the chromatin regulatory system, supporting the identification and validation of potential therapeutic targets. The company's flagship program is FHD-909.
Ticker
$FHTX
Sector
Primary listing
Employees
106
Headquarters
Website
FHTX Metrics
BasicAdvanced
$294M
-
-$1.18
3.12
-
Price and volume
Market cap
$294M
Beta
3.12
52-week high
$6.95
52-week low
$2.94
Average daily volume
168K
Financial strength
Current ratio
2.733
Quick ratio
2.66
Long term debt to equity
-37.186
Total debt to equity
-38.037
Profitability
EBITDA (TTM)
-78.775
Gross margin (TTM)
-176.51%
Net profit margin (TTM)
-240.33%
Operating margin (TTM)
-265.64%
Revenue per employee (TTM)
$290,000
Management effectiveness
Return on assets (TTM)
-21.29%
Return on equity (TTM)
96.45%
Valuation
Price to revenue (TTM)
10.188
Price to book
-2.61
Price to tangible book (TTM)
-2.61
Price to free cash flow (TTM)
-3.655
Free cash flow yield (TTM)
-27.36%
Free cash flow per share (TTM)
-1.368
Growth
Revenue change (TTM)
36.75%
Earnings per share change (TTM)
-25.25%
3-year revenue growth (CAGR)
17.14%
3-year earnings per share growth (CAGR)
-23.34%
What the Analysts think about FHTX
Analyst ratings (Buy, Hold, Sell) for Foghorn Therapeutics stock.
FHTX Financial Performance
Revenues and expenses
FHTX Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Foghorn Therapeutics stock?
Foghorn Therapeutics (FHTX) has a market cap of $294M as of March 23, 2026.
What is the P/E ratio for Foghorn Therapeutics stock?
The price to earnings (P/E) ratio for Foghorn Therapeutics (FHTX) stock is 0 as of March 23, 2026.
Does Foghorn Therapeutics stock pay dividends?
No, Foghorn Therapeutics (FHTX) stock does not pay dividends to its shareholders as of March 23, 2026.
When is the next Foghorn Therapeutics dividend payment date?
Foghorn Therapeutics (FHTX) stock does not pay dividends to its shareholders.
What is the beta indicator for Foghorn Therapeutics?
Foghorn Therapeutics (FHTX) has a beta rating of 3.12. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.